Cabozantinib, a multi-target TKI, including VEGFR2 and MET, with immunomodulatory properties, was combined with durvalumab in the CAMILLA phase I/II trial in different gastrointestinal tumors, including microsatellite stable (MSS) CRC, which is associated with a poorer response to immunotherapy (see below, under “Avoiding Immune Destruction”). This evidence concerns the gene KDR and colorectal carcinoma.